Home > Insider Trading > Filing (0001209191-21-004452)

Filing Details

Accession Number:: 0001209191-21-004452
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-01-20 18:05:14
Reporting Period:: 2021-01-19

Accepted Time:: 2021-01-20 18:05:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1674416	Crispr Therapeutics Ag	CRSP	Biological Products, (No Disgnostic Substances) (2836)	473173478

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1708172	R. James Kasinger	C/O Crispr Therapeutics, Inc. 610 Main Street Cambridge MA 02139	General Counsel And Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2021-01-19	27,500	$51.49	49,931	No	4	M	Direct
Common Shares	Disposition	2021-01-19	6,785	$203.58	43,146	No	4	S	Direct
Common Shares	Disposition	2021-01-19	7,818	$204.40	35,328	No	4	S	Direct
Common Shares	Disposition	2021-01-19	8,997	$205.60	26,331	No	4	S	Direct
Common Shares	Disposition	2021-01-19	1,800	$206.05	24,531	No	4	S	Direct
Common Shares	Disposition	2021-01-19	2,100	$207.61	22,431	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (right to buy)	Disposition	2021-01-19	27,500	$0.00	27,500	$51.49

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,500		2028-03-07	No	4	M	Direct

Footnotes

Includes 16 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.00 to $203.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $204.00 to $204.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $205.00 to $205.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $206.00 to $206.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $207.39 to $208.1050, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on March 7, 2018 with respect to 40,000 Common Shares and vests in 48 equal monthly installments.